Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTLI.L Regulatory News (TLI)

  • There is currently no data for TLI

Interim Management Statement

24 Nov 2011 16:15

RNS Number : 7467S
Alternative Asset Opps PCC Ltd
24 November 2011
 



 

 

24 November 2011

Alternative Asset Opportunities PCC Limited

(the "Company")

Interim Management Statement

 

This interim management statement relates to the period from 1 July 2011 to the date of publication of this statement and has been prepared solely to provide additional information in order to meet the relevant requirement of the UK Listing Authority's Disclosure and Transparency Rules, and should not be relied on by Shareholders, or any other party, for any other purpose.

 

The Company is a closed-ended Guernsey protected cell company with one cell known as the US Traded Life Interests Fund (the "Fund").

 

Investment objective

The Company's investment objective in respect of the Fund is to provide investors with an attractive capital return through investment predominantly in a diversified portfolio of US Traded Life Interests ("TLIs").

 

Financial position and performance

Over the period to 31 October 2011, the Company's net asset value per share decreased by 7.0% to 71.8 pence. As at 31 October 2011, the shares were trading at a 38.0% discount to net asset value.

 

Two policy maturities on a single life were identified during the period, and policy maturity proceeds were received during October 2011 adding circa 1.8 pence to the NAV per share. There will then have been, in aggregate, 32 policy maturities since the Fund's inception.

 

The Company's loan agreement with Allied Irish Banks plc ("AIB") expired on 31 July 2011, and pending the necessary approvals, AIB switched the loan to "repayment on demand", allowing the Company to continue fulfilling its obligations, including the payment of premiums. Following all the necessary approvals from AIB and the Central Bank of Ireland the loan agreement was renewed to cover the necessary funding up to the end of March 2012. As at 31 October 2011, total borrowings under the agreement amounted to US$23,192,000.

 

At an Extraordinary General Meeting on 20 September 2011 it was resolved to change the Company's investment policy to remove the requirement to hedge the currency exposure of the assets of the Fund into Sterling. Following agreement with AIB, the Directors have subsequently closed out its existing forward sale contracts of the remaining US$66 million, realising a loss of £7,388,291 to be settled at the end of March 2012.

 

At the same Extraordinary General Meeting on 20 September 2011 it was also resolved to amend the Company's Articles of Incorporation to increase the Company's borrowing limit from 50% to 75% of the Fund's NAV. This was as a result of the losses referred to above and the resulting requirement of an increase in the Company's borrowings, which would in the absence of policy maturities or policy sales, result in a ratio of approximately 65%.

The Board is not aware of any other material events during the period from 1 July 2011 to 31 October 2011, or in the period from 1 November 2011 to the date of this announcement, which would have had a material impact on the financial position of the Company.

 

In previous reports, the Board has attempted to give investors an appreciation of the effects on valuation of differing assumptions as to both LE and IRR. These tables have tended to become quite complex, and the Board has been considering how best to improve them. The new, simplified illustrative 'Sensitivity Matrix' set out below is, in the first place, now expressed in terms of NAV per share, an easier concept to understand than that previously used (based on IRR to an assumed maturity date). Secondly, the tables now enable the Board to show the effect of differing market IRR assumptions.

- The first line of NAVs in the new table uses the 'Latest LE' assumption, that is to say either an LE based on a recently updated assessment or, for the remaining 34% of the portfolio by face value (the 'non-updated policies'), based on the original LE assessed at the time of purchase. The average LE (weighted by policy value) is shown for reference (4.75 years). NAV is then shown at four different discount rates, ranging from 10% to 20%. This shows the effect of IRR on current value, but it also allows investors to assess the effects of forced sales if, for example, the portfolio was to be liquidated before 31 December 2016.

 

- The second line uses the assumption that updated LEs obtained for the non-updated polices would broadly follow those already obtained for other policies, resulting in an LE increase of 20% on the non-updated policies. In practice, the LE changes exhibited by actual revised assessments vary widely and the Board does not feel it is necessarily correct to extrapolate the changes for the non-updated policies. The overall effect is to increase average LE by 0.21 years.

 

- The third line assumes an increase in LE of 40% on the non-updated policies. The effect on NAV is roughly proportionate to that shown in the second line, but the increase in LE is only 0.1 years because of the fact that policies are weighted by value - such an extension to LE of course has significant impact on the values of some of these policies.

 

- Finally, the fourth line shows the outcome of assuming LEs are simply based on the current table of life expectancies for the general population, the 2008 Valuation Basic Table (Ultimate), i.e. ignoring LE assessments. The Board does not suggest that this is a realistic assumption, but it gives a measure of the degree to which the portfolio is dependent on assessed LEs being shorter than for the population as a whole.

 

 

Sensitivity Matrix

Net Asset Value in pence per share on various assumptions as at 31 October 2011

 

Mortality Assumptions

Weighted Average LE*

Discount Rates applied to cash flows

10%

Current (12%)

16%

20%

Latest LE

4.7

79.1

71.5

59.6

49.9

+20% for LE dates before 01/11/2008

5.0

70.3

63.1

51.6

42.5

+40% for LE dates before 01/11/2008

5.0

62.7

55.9

44.9

36.4

No underwriting

5.7

60.7

53.1

41.3

32.0

 

* The weighted average LE (in years) is calculated by reference to the policy values obtained.

 

 

Source: SL Investment Management Limited

 

 

 

Top ten holdings

By reference to the most recent portfolio valuation of the Company as at 31 October 2011, the largest ten investments held by the Company, measured by life office exposure, were as follows:

 

Issuer

Number of policies

% of totalassets as at31 October 2011

American General Life Insurance Company (TX)

13

17.54%

Transamerica Life Insurance Company

21

14.47%

Lincoln National Life Insurance Co

16

14.46%

Massachusetts Mutual Life Insurance Co

9

9.85%

John Hancock Life Insurance Company

11

8.24%

Aviva Life and Annuity Company

5

4.89%

MetLife Insurance Company of Connecticut

8

4.71%

New York Life Insurance and Annuity Corp

6

3.87%

Security Life of Denver Insurance Co

1

3.46%

National Western Life Insurance Company

1

2.62%

 

Company Information

 

Launch date 25 March 2004

EPIC TLI

Year end 30 June (from 2010 onwards)

Report & Accounts 2011 Annual Report posted October, Interim posted February

AGM November

Price Information Financial Times (under INVESTMENT COMPANIES, listed as 'AltAstsOpps.')

 

Investor Information

 

The latest available portfolio information included in the interim and annual report and accounts can be accessed via http://www.rcm.com/investmenttrusts/investors_tlif.php (under the Professional Investors section).

 

By order of the Board

Alternative Asset Opportunities PCC Limited

 

Enquiries:

Peter Ingram

Company Secretary Tel: 020 7065 1467

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSPGGWGGUPGGQC
Date   Source Headline
15th Dec 201511:29 amRNSDirector Declaration
2nd Dec 201511:03 amRNSListing Rule 15.6.8
13th Nov 20152:31 pmRNSNet Asset Value(s)
5th Nov 20158:58 amRNSAGM Statement
4th Nov 20152:48 pmRNSListing Rule 15.6.8
27th Oct 201510:13 amRNSHolding(s) in Company
23rd Oct 20159:48 amRNSHolding(s) in Company
22nd Oct 20154:26 pmRNSHolding(s) in Company
20th Oct 201510:54 amRNSNet Asset Value(s)
13th Oct 201511:50 amRNSAnnual Financial Report
5th Oct 20155:12 pmRNSHolding(s) in Company
5th Oct 20151:58 pmRNSListing Rule 15.6.8
2nd Oct 20152:12 pmRNSHolding(s) in Company
24th Sep 20151:05 pmRNSHolding(s) in Company
23rd Sep 20151:10 pmRNSPolicy Maturity
16th Sep 20152:55 pmRNSNet Asset Value(s)
16th Sep 20152:10 pmRNSPolicy Maturity
16th Sep 201511:30 amRNSAnnual Financial Report
2nd Sep 201510:43 amRNSListing Rule 16.5.8
20th Aug 20154:32 pmRNSPolicy Maturity
17th Aug 20154:08 pmRNSNet Asset Value(s)
12th Aug 20151:04 pmRNSListing Rule 15.5.(4)
12th Aug 201511:36 amRNSLoan Facility
4th Aug 201511:11 amRNSListing Rule 15.6.8
20th Jul 201512:51 pmRNSNet Asset Value(s)
2nd Jul 201511:14 amRNSListing Rule 15.6.8
23rd Jun 20153:35 pmRNSHolding(s) in Company
16th Jun 20157:00 amRNSNet Asset Value(s)
2nd Jun 201510:10 amRNSListing Rule 15.6.8
18th May 20152:06 pmRNSDirector/PDMR Shareholding
15th May 20154:13 pmRNSNet Asset Value(s)
5th May 20151:25 pmRNSListing Rule 15.6.8
16th Apr 201512:15 pmRNSNet Asset Value(s)
2nd Apr 20153:28 pmRNSListing Rule 15.6.8
16th Mar 20159:36 amRNSNet Asset Value(s)
3rd Mar 20158:50 amRNSListing Rule 15.6.8
27th Feb 20157:00 amRNSHalf Yearly Report
17th Feb 201511:38 amRNSNet Asset Value(s)
3rd Feb 201510:55 amRNSListing Rule 15.6.8
19th Jan 201510:20 amRNSPolicy Maturity
16th Jan 201510:04 amRNSNet Asset Value(s)
5th Jan 20151:24 pmRNSListing Rule 15.6.8
16th Dec 201410:53 amRNSNet Asset Value(s)
2nd Dec 20141:50 pmRNSListing Rule 15.6.8
28th Nov 20142:42 pmRNSChange of Name of Manager
27th Nov 201411:51 amRNSPolicy Maturity
24th Nov 201410:25 amRNSHolding(s) in Company
24th Nov 201410:03 amRNSPolicy Maturity
17th Nov 20142:08 pmRNSNet Asset Value(s)
12th Nov 20142:57 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.